ESR1 and invasive ductal breast carcinoma: It exhibits poor outcomes andsuboptimal responses to systemic chemotherapy compared with standard invasive ductal carcinomas [50].MBC is typically triple-negative and deficient in the expression of HER2, progesterone receptor (PR) and the estrogen receptor (ER)[51, 52].